Single-Chain Antibody-Based Immunotoxins Targeting Her2/Neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-11-0519
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Molecular Engineering of High Affinity Single-Chain Antibody Fragment for Endothelial Targeting of Proteins and Nanocarriers in Rodents and Humans

Journal of Controlled Release
Pharmaceutical Science
2016English

HER2/neu: An Increasingly Important Therapeutic Target. Part 2: Distribution of HER2/neu Overexpression and Gene Amplification by Organ, Tumor Site and Histology

Clinical Investigation
2014English

Spectral Fluorescence Molecular Imaging of Lung Metastases Targeting HER2/neu

Clinical Cancer Research
Cancer ResearchOncology
2007English

Construction and Characterization of Novel, Completely Human Serine Protease Therapeutics Targeting Her2/Neu

Molecular Cancer Therapeutics
Cancer ResearchOncology
2013English

699. shRNA Sense Strand Neutralization Reduces Off-Targeting, Ameliorates Toxicity and Enhances Efficacy of RNAi-Based HBV Gene Therapy

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2015English

Activating Mutations in HER2 : Neu Opportunities and Neu Challenges

Cancer Discovery
Oncology
2013English

Targeting Adenoviruses With Factor X–Single-Chain Antibody Fusion Proteins

Human Gene Therapy
Molecular MedicineGeneticsMolecular Biology
2010English

Targeting Nanodisks via a Single Chain Variable Antibody – Apolipoprotein Chimera

Biochemical and Biophysical Research Communications
BiochemistryCell BiologyMolecular BiologyBiophysics
2009English

Affinity Maturation of Monoclonal Antibody 1E11 by Targeted Randomization in CDR3 Regions Optimizes Therapeutic Antibody Targeting of HER2-Positive Gastric Cancer

PLoS ONE
Multidisciplinary
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy